LivaNova (NASDAQ:LIVN) Issues FY 2022 Earnings Guidance

LivaNova (NASDAQ:LIVNGet Rating) updated its FY 2022 earnings guidance on Wednesday. The company provided EPS guidance of $2.50-$2.80 for the period, compared to the consensus EPS estimate of $2.59. The company issued revenue guidance of $1.07 billion-$1.09 billion, compared to the consensus revenue estimate of $1.04 billion.

A number of research firms have recently commented on LIVN. Needham & Company LLC cut their target price on shares of LivaNova from $120.00 to $106.00 and set a buy rating for the company in a research note on Thursday, February 24th. StockNews.com assumed coverage on shares of LivaNova in a research note on Thursday, March 31st. They set a hold rating for the company. Zacks Investment Research cut shares of LivaNova from a hold rating to a sell rating in a research note on Tuesday. Piper Sandler dropped their price objective on shares of LivaNova from $104.00 to $99.00 in a research note on Thursday, May 5th. Finally, Wolfe Research assumed coverage on shares of LivaNova in a research note on Tuesday, April 5th. They set an outperform rating and a $95.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average price target of $100.71.

NASDAQ:LIVN opened at $60.69 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 0.82. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of -30.50 and a beta of 0.91. The company’s 50-day moving average is $78.20 and its two-hundred day moving average is $80.19. LivaNova has a 1-year low of $58.18 and a 1-year high of $93.89.

LivaNova (NASDAQ:LIVNGet Rating) last posted its earnings results on Wednesday, May 4th. The company reported $0.48 earnings per share for the quarter, meeting the consensus estimate of $0.48. The company had revenue of $240.20 million for the quarter, compared to analyst estimates of $231.57 million. LivaNova had a negative net margin of 9.69% and a positive return on equity of 9.57%. LivaNova’s revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.35 EPS. As a group, equities analysts anticipate that LivaNova will post 2.6 earnings per share for the current fiscal year.

In other news, CEO Damien Mcdonald sold 2,784 shares of the company’s stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $81.50, for a total value of $226,896.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $83.42, for a total transaction of $83,420.00. Following the completion of the transaction, the director now owns 24,630 shares in the company, valued at $2,054,634.60. The disclosure for this sale can be found here. Insiders sold a total of 5,784 shares of company stock worth $470,316 over the last quarter. 0.37% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of LIVN. BNP Paribas Arbitrage SA increased its stake in LivaNova by 24.6% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,586 shares of the company’s stock worth $680,000 after buying an additional 1,694 shares during the period. UBS Group AG increased its stake in LivaNova by 8.0% during the 3rd quarter. UBS Group AG now owns 22,652 shares of the company’s stock worth $1,794,000 after buying an additional 1,678 shares during the period. Deutsche Bank AG increased its stake in LivaNova by 3.6% during the 4th quarter. Deutsche Bank AG now owns 36,769 shares of the company’s stock worth $3,214,000 after buying an additional 1,261 shares during the period. Amalgamated Bank increased its stake in LivaNova by 0.5% during the 4th quarter. Amalgamated Bank now owns 37,437 shares of the company’s stock worth $3,273,000 after buying an additional 173 shares during the period. Finally, Credit Suisse AG increased its stake in LivaNova by 3.2% during the 4th quarter. Credit Suisse AG now owns 46,997 shares of the company’s stock worth $4,109,000 after buying an additional 1,467 shares during the period. Hedge funds and other institutional investors own 97.34% of the company’s stock.

LivaNova Company Profile (Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Read More

Earnings History and Estimates for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.